AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa.
The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.
It also provides PhenoCycler and PhenoImager reagents; and biopharma services.
In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI.
The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Country | United States |
IPO Date | Apr 16, 2021 |
Industry | Medical - Instruments & Supplies |
Sector | Healthcare |
Employees | 330 |
CEO | Brian McKelligon |
Contact Details
Address: 100 Campus Drive Marlborough, Massachusetts United States | |
Website | https://www.akoyabio.com |
Stock Details
Ticker Symbol | AKYA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001711933 |
CUSIP Number | 00974H104 |
ISIN Number | US00974H1041 |
Employer ID | 47-5586242 |
SIC Code | 3826 |
Key Executives
Name | Position |
---|---|
Brian McKelligon | President, Chief Executive Officer & Director |
Dr. Niro Ramachandran Ph.D. | Chief Business Officer |
Dr. Pascal Bamford Ph.D. | Senior Vice President, Research & Development and Laboratory Operations |
Jennifer Kamocsay | General Counsel |
Priyam Shah | Senior Director of Business Development & Investor Relations Strategy |
Rob C. Hart CFA, J.D. | Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 14, 2025 | 425 | Filing |
Jan 10, 2025 | 425 | Filing |
Jan 10, 2025 | 425 | Filing |
Jan 10, 2025 | 425 | Filing |
Jan 10, 2025 | 8-K | Current Report |
Jan 10, 2025 | 425 | Filing |
Dec 13, 2024 | 8-K | Current Report |
Nov 21, 2024 | 4 | Filing |
Nov 21, 2024 | 4 | Filing |
Nov 21, 2024 | 4 | Filing |